We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Biosimilar Trastuzumab, developed jointly by BIOCON Ltd. and Mylan NV, has been approved by the Brazilian regulator ANVISA through its partner Libbs Farmaceutica (Libbs), a leading Brazilian pharmaceutical company.